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Background: Among the S1 family of serine proteinases, the blood coagulation
factor IXa (fIXa) is uniquely inefficient against synthetic peptide substrates.
Mutagenesis studies show that a loop of residues at the S2–S4 substrate-
binding cleft (the 99-loop) contributes to the low efficiency. The crystal
structure of porcine fIXa in complex with the inhibitor D-Phe-Pro-Arg-chloro-
methylketone (PPACK) was unable to directly clarify the role of the 99-loop, as
the doubly covalent inhibitor induced an active conformation of fIXa.
Results: The crystal structure of a recombinant two-domain construct of human
fIXa in complex with p-aminobenzamidine shows that the Tyr99 sidechain
adopts an atypical conformation in the absence of substrate interactions. In this
conformation, the hydroxyl group occupies the volume corresponding to the
mainchain of a canonically bound substrate P2 residue. To accommodate
substrate binding, Tyr99 must adopt a higher energy conformation that creates
the S2 pocket and restricts the S4 pocket, as in fIXa–PPACK. The energy cost
may contribute significantly to the poor KM values of fIXa for chromogenic
substrates. In homologs, such as factor Xa and tissue plasminogen activator,
the different conformation of the 99-loop leaves Tyr99 in low-energy
conformations in both bound and unbound states.
Conclusions: Molecular recognition of substrates by fIXa seems to be
determined by the action of the 99-loop on Tyr99. This is in contrast to other
coagulation enzymes where, in general, the chemical nature of residue 99
determines molecular recognition in S2 and S3–S4. This dominant role on
substrate interaction suggests that the 99-loop may be rearranged in the
physiological fX activation complex of fIXa, fVIIIa, and fX.
Introduction
The serine proteinases of the coagulation cascade, together
with cofactors, amplify initial procoagulant signals via a
series of activation cleavages to produce thrombin.
Thrombin then stimulates platelets to aggregate, activates
fibrinogen to stabilize the nascent clot, and activates
protein C to ultimately terminate the process [1,2]. Of the
proteinase coagulation factors, fIXa has been noted for its
low amidolytic efficiency [3–5] and for its association with
hemophilia [6]. fIXa is composed of an N-terminal γ-car-
boxyglutamic acid rich (Gla) domain, followed by two epi-
dermal growth factor (EGF) like repeats, an activation
peptide and a serine proteinase domain with trypsin-like
specificity (arginine or lysine at P1) [2,7]. (Pn and Pn′
denote the nth amino acid N- or C-terminal from the
cleavage site; Sn and Sn′ denote the corresponding
binding sites of the protease.) Following vessel injury, fIX
is converted to the active two-chain form fIXaβ by factor
XIa or the factor VIIa (fVIIa)–tissue factor complex [8–10],
the initiator of the clotting cascade [11]. fIXaβ assembles
with its cofactor, fVIIIa, on the surface of endothelial cells
or activated platelets [12,13], giving rise to the intrinsic
Xase, the principal activator of factor X. The Xase has a
106–107 times higher catalytic efficiency towards fX than
fIXa alone [14]. Part of this enhancement can be attrib-
uted to the confinement to a two-dimensional surface [15].
The remaining enhancement, however, is triggered by
fVIIIa and involves an as yet unknown mechanism, which
presumably involves changes in the conformation of the
substrate and/or the enzyme [14].
Besides begging explanation, the uniquely poor amidolytic
activity of fIXa complicates efforts to develop substrates
and inhibitors for fIXa. Other clotting factors cleave syn-
thetic peptides containing natural substrate sequences with
catalytic efficiencies (kcat/KM values) in the range of 105–106
M–1 sec–1 [16], but virtually no activity is found for fIXa
towards substrates containing the fX activation sequence
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[4]. Furthermore, neither synthetic fIXa substrates with
kcat/KM > 103 M–1 sec–1 nor potent low molecular weight
active site directed fIXa inhibitors with Ki <1 µM have
been found (a ‘typical’ therapeutic inhibitor has a Ki in the
low nanomolar range). Significant enhancement of catalysis
(up to 40-fold) is observed in the presence of specific
mostly bifunctional alcohols [17], but the mechanism is
unknown. Improved fIXa substrates and inhibitors could,
for example, accelerate screening assays, enhance diagnos-
tic sensitivities, and facilitate purification, among cardiovas-
cular research or other biotechnological applications. 
The crystal structure of porcine fIXa inhibited with the sub-
strate analog D-Phe-Pro-Arg-chloromethylketone (PPACK)
showed several features likely to be relevant for the fIXa
low chromogenic substrate activity [18]. Although the
active site closely resembled that of the much more reac-
tive fXa [19,20], two residues in the vicinity of the PPACK
inhibitor, Glu219 and Tyr99 (here we use chymotrypsino-
gen numbering for the catalytic domain and fIXa number-
ing preceded by ‘L’ for residues of the EGF2 domain),
seemed particularly remarkable. Glu219 is located at the
entrance frame of the S1 pocket and is strictly conserved
among fIXa sequences, but is conserved as a glycine in
other trypsin-like enzymes. Its backbone conformation is
relatively rare for nonglycine residues, which led to the
proposal that an energetically strained S1 pocket is stabi-
lized by the covalently bound PPACK but may adopt
other conformations in uninhibited fIXa [18]. Although the
mutation Glu219→Gly did not increase the amidolytic
activity of fIXa, the diminished fXa activity resulting from
the reverse Gly219→Glu mutation indicated the impor-
tance of Gly219 for catalysis [21]. Swapping the fXa
99-loop sequence for that of fIXa did, however, increase
the amidolytic activity of fIXa 25-fold [21]. The 99-loop
borders the S2–S4 sites, whereby residue 99 determines
the size and chemical environment of the S2 and S4
pockets [22]. Although both fIXa and fXa have a tyrosine
at position 99, the sidechain orientations differ signifi-
cantly between the structures [18,19]. In fIXa–PPACK,
Tyr99 blocks the S4 subsite, whereas in fXa it points
towards the S2 site in a similar manner to that observed in
glandular kallikrein [23,24] and tissue-type plasminogen
activator (tPA) [25,26]. The interpretation of these obser-
vations is complicated by the presence of different ligands
in the active sites in these structures. In particular, the
covalently bound PPACK inhibitor in the porcine fIXa
structure was thought to have induced an active conforma-
tion, which possibly included a reorientation of Tyr99 [18].
To explore the structural origins of fIXa’s poor reactivity
we have determined the crystal structure of a recombinant
two-domain construct (EGF2–catalytic) of human fIXa
(rfIXa) in complex with p-aminobenzamidine (PABA) to
2.8 Å resolution. PABA leaves the S2–S4 sites unoccupied.
In this structure, the relaxed conformation of Tyr99 indeed
differs from the conformation seen in fIXa–PPACK and
would block substrate binding. The uniqueness of this
conformation is demonstrated by a comparison with other
serine proteinases and may explain fIXa’s generally poor
substrate recognition; it may also reflect a possible mecha-
nism for cofactor fVIIIa stimulation. Furthermore, the
structure suggests strategies for engineering fIXa mutants
with enhanced activities and ways for improving fIXa sub-
strates and inhibitors.
Results and discussion
Overall structure
In general, the two domains (catalytic and EGF2) of the
rfIXa–PABA complex described here (Figure 1) closely
resemble their counterparts in the PPACK-inhibited
porcine fIXa [18]. The catalytic domain, with the typical
chymotrypsin fold, is composed of two β-barrel subdomains
that form the active site at their common interface; the sub-
strate-binding cleft runs perpendicular to this junction.
The EGF2 module is attached to the pole of the catalytic
domain opposite the active site and is covalently linked to
it by a disulfide bridge. The activation peptide — the
sequence linking EGF2 with the catalytic domain — is
excised upon activation, leaving the activating N terminus
of the heavy chain (Val16 in chymotrypsinogen numbering)
in the typical buried salt bridge with Asp194. The three
disulfide bridges of the catalytic domain are correctly
formed, and the C-terminal residues adopt the characteris-
tic helix structure running across the N-terminal β barrel.
All surface loops of the catalytic domain were visible in the
electron density and were folded in a similar manner to
those of porcine fIXa, with minor differences probably
owing to crystal-packing effects.
The light chain of rfIXa consists of the EGF2 domain and
a few residues of the linker peptide between the EGF2
domain and the catalytic domain. The EGF2 module is
folded into five consecutive strands of β strand topology,
which are connected by four hairpin loops. Strands 2 and 3
and strands 4 and 5 form a major and a minor β pleated
sheet, respectively. The strands are interconnected by
three disulfide bridges of the EGF-characteristic 1–3, 2–4,
5–6 topology.
The structure of full-length porcine fIXa showed that a
salt bridge links EGF1 and EGF2 via the conserved fIXa
residues GluL78 and ArgL94, presumably anchoring their
relative orientations [18]; this hypothesis was subsequently
tested and confirmed by mutagenesis experiments [27]. In
the EGF2 module of rfIXa, the sidechain of ArgL94 is dis-
ordered, as are the N-terminal residues and also sidechain
atoms of the hairpin loop connecting strand 2 with strand
3. As these elements are ordered and form various contacts
with EGF1 in full-length fIXa–PPACK, the observed dis-
order is evidence that interactions with the EGF1 domain
contribute to ordering in the EGF2 domain.
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The EGF2 module interacts across a broad interface with
the catalytic domain, and is also covalently attached across
a conserved disulfide bridge between CysL132 (EGF2)
and Cys122 (catalytic domain). The remaining peptide that
connects the EGF2 module to the catalytic domain — part
of which is excised upon activation — folds into a depres-
sion formed between the two β barrels of the catalytic
domain. In addition to the interdomain disulfide bridge,
several interactions attach the EGF2 module tightly to the
catalytic domain. These include a salt bridge between
Lys239 of the C-terminal helix of the catalytic domain with
GluL113, and the burial of PheL98 into an aromatic cluster
formed by Tyr128, Phe130 and Phe133.
Crystal packing
The crystal lattice structure, the solvent content of the
crystal (56%), and the absence of covalent or tight binding
inhibitors make the crystals described here particularly
well suited for low molecular weight fIXa inhibitor
soaking experiments. The crystal packing leaves a large
space around the active site free and the substrate-binding
cleft is unoccupied by residues from symmetry-related
molecules. Crystal contacts involve the 37-loop, the 60-
loop and the 148-loop, located at the primed side of the
binding cleft (Figure 1). The unprimed side, formed by
the 99- and 170-loops is uninfluenced by crystal packing.
Hence, this rfIXa construct might prove especially useful
for the development of fIXa-specific substrates and
inhibitors with applications in antithrombotic therapies.
The calcium-binding site
rfIXa was crystallized in the presence of calcium. fIX con-
tains a calcium-binding site in the catalytic domain
(Kd ~300 µM) that influences amidolytic activity and
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Figure 1
The structure of the recombinant two-domain
(catalytic and EGF2) construct of human fIXa.
(a) Ribbon model of fIXa oriented with the
catalytic domain (yellow) in front and the
EGF2 domain (orange) behind. The active site
is situated at the opposite pole of the EGF2
domain, at the central front of the catalytic
domain with the substrate-binding cleft
running from left to right. The PABA inhibitor in
the S1 pocket and residue Tyr99 at the S2
site are shown as magenta and cyan ball-and-
stick models, respectively. The seven disulfide
bridges (three in the catalytic domain, three in
the EGF2 domain, and one connecting both
domains) are shown in green ball-and-stick
representation. The calcium ion is shown as a
gray ball. (b) Stereoview Cα trace of human
rfIXa (thick lines) superimposed with full-length
porcine fIXa (thin lines). Bound PABA is
shown in black ball-and-stick representation.
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exposure of the 148-loop (autolysis loop) for proteolytic
cleavage [28,29]. We find clearly interpretable electron
density in the cavity formed by the sidechains of residues
Glu70, Glu77 and Glu80 and the mainchain oxygens of
Asn72 and Glu75. The geometry of the calcium-binding
site closely resembles that of porcine fIXa (Figure 1), which
was crystallized without calcium. The calcium-binding site
in the catalytic domain of fIXa thus appears largely pre-
formed. (In contrast, the low-affinity calcium-binding sites
in the Gla-rich domain are formed by an ordered transition
upon calcium binding.) The observed calcium-binding
dependence on activity might arise by formation of the
Asn72 O–calcium bond and consequent rigidification of the
70-loop propagated to the adjacent 148-loop.
The active site
The S1 pocket of the active site is occupied by PABA, as
clearly defined in the electron density (Figure 2). The PABA
amidino group forms a twin–twin salt bridge with Asp189.
No solvent molecules were detected in the S1 site. All other
unprimed subsites of the substrate-binding cleft appear
unoccupied, including consideration of symmetry-related
molecules, and are uninfluenced by crystal contacts. Density
at the S2′ site can be interpreted as t-butanol, one of several
alcohols that enhance fIX activity [17]. It remains unclear,
however, whether this potential binding site is linked to the
alcohol-induced stimulation of reactivity. Two active-site
residues, Glu219 at S1 and Tyr99 at S2, are of particular
interest, having been proposed as potential causes for fIXa’s
poor reactivity [18,21] based on the hypothesis that the
active, but possibly strained, conformations observed in
fIXa–PPACK were induced by inhibitor binding.
Glu219, located at the entrance frame of the S1 pocket, is
replaced by a glycine in other trypsin-like enzymes [30].
Its backbone geometry is similar in both fIXa structures,
but with different sidechain orientations. As observed in
the structure of fIXa–PPACK [18], Glu219 had a back-
bone conformation (φ = 55°, ψ = –164°) once considered
disallowed for nonglycine residues. This lead to the sug-
gestion that removal of the doubly covalent PPACK might
destabilize the S1 pocket, leading, for example, to disorder
of the Glu219 backbone and its surroundings — analogous
to a zymogen-like state [31]. In the structure of
fIXa–PABA, where the S1 site is also occupied, Glu219
has a similar conformation (φ = 58°, ψ = –154°). However,
the Glu219 carbonyl oxygen is clearly positioned within
the electron density and forms a hydrogen bond to one
amidino nitrogen of PABA (Figure 2). This backbone con-
formation occurs with sufficient frequency among nong-
lycine residues to consider it allowed, although not most
favored [32]. Here, the conformation is stabilized by three
interactions. Firstly, its two neighboring residues are both
fixed, either by a disulfide bridge (Cys220–Cys191) or by
a salt bridge (Glu217–Lys224). Secondly, the carboxyl
moiety forms a salt bridge, either to Arg148 (porcine fIXa)
or to Lys224 (rfIXa). Thirdly, the carbonyl oxygen of
Glu219 shares a hydrogen bond with either a guanidinium
nitrogen of the PPACK arginine residue or an amidino
nitrogen of PABA. The first two interactions fix the geom-
etry, whereas the third interaction is only present in the
inhibited enzyme and might stabilize the orientation of
the carbonyl oxygen of Glu219. On the one hand, the
higher energy of this conformation might suggest the
occurrence of alternate conformations in the unbound
state as suggested previously. On the other hand, the
restriction of this conformation to a small local Ramachan-
dran energy minimum might increase the rigidity of the
backbone compared to serine proteinases with glycine at
this position. This could lower the ability of the enzyme to
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Figure 2
The active site of the refined model of rfIXa
displayed with the final 2Fo–Fc electron density
contoured at 1.0σ. The orientation of fIXa is
taken from Figure 1. fIXa is shown as a stick
model with atoms colored by type: carbon,
yellow; nitrogen, blue; oxygen, red; and sulfur,
green. The carbon atoms of PABA are colored
purple. The t-butanol molecule, located in the
S1′–S2′ site, is shown in cyan. The orientation
of the Tyr99 sidechain is unambiguously
determined in the electron density. 
accommodate inhibitor binding. Whether the structure of
the uninhibited enzyme is more flexible or disordered will
require further investigation (initial attempts to wash the
PABA from our crystal were not successful).
Free Tyr99 relaxes to a substrate-blocking conformation
The most striking feature of PABA-inhibited rfIXa com-
pared to PPACK-inhibited fIXa is a ~60° χ1 rotation of the
Tyr99 sidechain. In the rfIXa–PABA structure, the Tyr99
phenol occupies the volume usually corresponding to the
S2 site, whereas in the fIXa–PPACK structure it restricts
the S4 pocket and the S2 site is occupied by the P2 proline
of PPACK. Superimposing both structures shows that the
conformation of Tyr99 in PABA-inhibited rfIXa would
interfere with the P2 mainchain of a canonically bound sub-
strate (Figure 3). In addition, S4 is not accessible for large
hydrophobic amino acid sidechains. Therefore, this
‘relaxed’ conformation of Tyr99 is incompatible with
‘canonical’ substrate binding, such that the Tyr99 sidechain
must rotate prior to substrate binding. Comparison with the
structure of homologs shows that this ‘relaxed’ position of
Tyr99 is unique for fIXa, blocking access to both the S2
and S4 site (Figure 3).
The 99-loop is rigid and fIX-specific 
The 99-loop folds in a very similar manner in both fIXa
structures, but differs considerably from that of homologs
such as fXa and tPA (Figure 3). Although the Cα atoms of
residues 94 and 99 (the flanking residues of the loop)
superimpose fairly well between fIXa and homologs, the
mainchain orientation of residue 99 and the positions of the
sequentially adjacent residues are different, leading in par-
ticular to the atypical orientation of Tyr99 in fIXa–PABA.
Several elements are likely to be responsible for this.
Firstly, and most conspicuously, the 99-loop of fIXa has a
conserved two-residue insertion compared to homologs
(Figure 4). Secondly, the carbonyl oxygen of Lys98 forms a
hydrogen bond to Tyr94, which stabilizes the fIXa 99-loop
geometry (Figure 3). Thirdly, a fXa/tPA-like conformation
of the 99-loop of fIXa would lead to a steric collision of
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Figure 3
Stereoview comparisons of substrate
recognition by fIXa and other homologs.
(a) The divergent structures of the fIXa
99-loop (yellow) compared with those of
factor Xa (white) and tPA (red) place Tyr99
either in a relaxed position that blocks
substrate binding in the S2 site (thick lines) or
in a strained position that blocks the S4 site
(thin lines). The inhibitor (purple, D-Phe-Pro-
Arg with proline atoms omitted for clarity)
position is taken from the superposition of
porcine fIXa. (b) The conformation of the fIXa
99-loop (yellow) is stabilized by a hydrogen
bond between Tyr94 (phenylalanine in fXa)
and Lys98, whereas the fXa 99-loop (gray)
conformation is prevented by the position of
Tyr177 (threonine in fXa).
Lys98 with Tyr177 (Figure 3); homologs have small
residues in both positions, usually threonine. In conclusion,
the 99-loop seems to be locked in fIXa in its unique confor-
mation by several interactions, such that induced conforma-
tional changes necessary for peptidic substrate binding are
restricted to the reorientation of the Tyr99 sidechain. 
Ligand-induced displacement of Tyr99 in fIXa introduces
strain
Comparing sidechain and backbone geometries of Tyr99
in fIXa and homologs with and without bound inhibitor at
site S2 shows that an adjustment of Tyr99 is required for
substrate binding (Figure 5). For fXa, tPA and kallikrein,
this reorientation occurs by a rotation of backbone dihedral
angle χ2 (if the inhibitor binds in the S2 site with glycine
as the P2 group) or by a rotation of χ2 accompanied by an
adjustment of the 99-loop (for proline at P2), as observed
for DEGR–sctPA (Dansyl-Glu-Gly-Arg-chloromethyl-
ketone-single chain tPA) [26] and fXYa–PPACK (fXYa is a
hybrid fXa–trypsin catalytic domain [33]). Rotation of χ1,
however, is neither necessary nor observed in any case.
Both observed orientations of Tyr99 are in a ‘relaxed’ con-
formation and the energy cost of the conformational
change is low, as judged by database-derived relative fre-
quencies [32] of χ1,χ2 angles (Figure 5). The orientation
of Tyr99 in rfIXa–PABA, however, requires a much larger
conformational change prior to substrate binding including
a 60° χ1 rotation observed for pfIXa–PPACK.
As apparent from the χ1,χ2 plot (Figure 5), this rotation
presumably does not reach an intrinsically relaxed
sidechain conformation. This would require a rotation of
120° about χ1 relative to its conformation in rfIXa–PABA.
Such a rotation would, however, place Tyr99 in steric
collision with Met180 after ~90° if there is no adjustment
of the Met180 sidechain. Consequently, Tyr99 in
pfIXa–PPACK adopts a high-energy conformation. The
energy cost of this conformational change may be a partial
cause of the poor Kd (and consequently KM) values for
enzyme–substrate interactions. Additionally, as a conse-
quence of the χ1 rotation, Tyr99 occupies the S4 subsite
and prevents binding of D-P3 or P4 residues into S4.
Mutation of Met180 to a smaller residue may remove this
hindrance and test the hypothesis; methionine and adja-
cent residues are, however, highly conserved. 
fIXa has an atypical selectivity profile for tyrosine at
position 99
The residue at position 99 shows considerable variability
among trypsin-like enzymes [30] and contributes to the ster-
ical and chemical properties of the S2 and S4 pockets [22].
There is a clear correlation between the residue at position
99 and the P2 specificity of the enzyme. This influence is
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Figure 4
An alignment of the amino acid sequences of 99-loops. Known fIXa
sequences are aligned with homologs fXa and tPA. Conserved
residues — relative to human fIXa — are boxed and shaded. 
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Figure 5
Analysis of the φ,ψ and χ1,χ2 values of residue
99. fIXa–PABA is compared with fIXa–PPACK
(PDB entry code 1PFX), tPA (1RTF, 1BDA),
fXa (1HCG, 1FAX, 1KIG), fXYa–PPACK
(1FXY) and kallikrein (1KAI, 1PKA, 1AO5). The
background and symbol colors indicate the
relative frequencies of observed conformations
found in proteins [32] and the approximate
corresponding conformation energies,
respectively. Rare occurrences (yellow
background) indicate strained conformations
(red symbols); common occurrences (green
background) indicate relaxed conformations
(yellow symbols). The coloring of the text
indicates the presence (red) or absence (black)
of substrate in the S2 binding site. (a) The φ,ψ
analysis. fIXa has unique φ,ψ values at position
99 that reflect the unique geometry of its 99-
loop. (b) The χ1,χ2 analysis. The fIXa
response to substrate binding is different from
that observed for other enzymes. For fIXa,
binding of substrate results in a χ1 rotation;
the resulting conformation is unfavorable. For
fXa, tPA and kallikrein, substrate interaction
results in a χ2 rotation; the resulting
conformations are favorable.
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demonstrated by site-directed mutagenesis, where swap-
ping residues at position 99 between fXa (Tyr99) and acti-
vated protein C (Thr99) swaps the substrate preference for
the P2 residue of both enzymes [31]. A bulky sidechain at
this position is in general associated with a preference for
small P2 residues. Natural substrates for fXa (Tyr99), tPA
(Tyr99) and urokinase (His99) have a glycine at P2,
whereas homologs that have a less bulky residue 99 have a
preference for larger residues such as proline, as in the case
of thrombin (Leu99) and activated protein C (Thr99).
fIXa does not follow these principles, however. Although it
has a tyrosine at position 99, its natural substrate, fXa, has a
threonine (human and chicken fXa) or a valine (bovine fXa)
at P2, rather than glycine. Furthermore, compared with
homologs, fIXa possesses a surprisingly poor catalytic activ-
ity for virtually any synthetic substrate, independent of the
size of the P2 amino acid [3,5], which seems to be a result of
defects in both KM and kcat values. These catalytic proper-
ties seem not to result solely from the presence of a tyrosine
at position 99, as fIXa’s closest homolog, fXa, is potent and
the presence of Tyr99 in fXa does not impair interactions
with substrates but simply creates the preference for
glycine at P2 [31]. Mutagenesis studies suggest an impor-
tant role of the 99-loop (rather than solely residue 99) in the
determination of fIXa’s amidolytic reactivity [21]. For
example, exchanging residues 95–98 to the corresponding
fXa sequence results in a 25-fold increase in reactivity with
lowered KM values, whereas the mutation Tyr99→Leu
seems to have virtually no effect on catalytic activity (KS
et al., unpublished data). This sequence dependence is con-
sistent with a role for the fIX-specific two-residue insertion
despite the equivalence of the 99 position. The relaxed
conformation of the active site in fIXa–PABA now provides
the structural basis for the role of this loop and explains
fIXa’s high KM values towards synthetic substrates.
In the Xase–fX complex, fVIIIa or fX may alter the 99-loop 
As one of either the S2 (relaxed) or the S4 (substrate-
bound) pockets is blocked by Tyr99, depending on its
conformation, an open peptide-binding cleft requires a
rearrangement of the 99 loop. As pointed out above, a con-
formation of the mainchain of residues 98–99 as observed
for homologs is unfavorable because of a collision of Lys98
with Tyr177 (preliminary experiments with a fIXa mutant
Lys98→Thr show a tenfold increase in amidolytic activity;
KS et al. unpublished results). Tyr177 is located in the
loop following the intermediate helix. It was suggested
that the intermediate helix contacts fVIIIa in the Xase-fX
complex [18]. In addition, crystal structures of related
enzyme–cofactor complexes — fVIIa with tissue factor
[34] and plasmin with staphylokinase [35] or streptokinase
[36] — show that the cofactor binds to or in the vicinity of
the intermediate helix. In the case of plasmin, which has
no corresponding 99-loop, the cofactor staphylokinase
functions by providing a substitute 99-loop [35].
Complex formation of fVIIIa with fIXa in particular
results in a 103-fold increase in the reactivity of fIXa
towards fX. Although there are no data indicating that
fVIIIa increases the amidolytic activity of fIXa towards
chromogenic substrates, for both the intrinsic fXase and
the homologous system fVa–fXa (prothrombinase) it was
shown that binding of the cofactor influences the active
site of the enzyme [37,38]. Taken together, these results
suggest that fVIIIa might influence the intermediate helix
(170-loop) and indirectly allow or induce a conformation of
the 99-loop that promotes canonical substrate binding.
Biological implications
The uniquely poor catalytic reactivity of the proteinase
coagulation factor fIXa is determined to a large extent by
a loop of residues termed the 99-loop. In contrast to
homologs, where the chemical nature of residue 99 deter-
mines the preference for substrate P2 residues, substrate
recognition of fIXa is determined by the 99-loop rather
than residue 99. Probably as a consequence of the unique
fold of the 99-loop, Tyr99 of fIXa blocks either the S2
site (with no substrate bound) or the S4 site (with sub-
strate bound). An open peptide-binding cleft that could
allow extended substrate binding requires a rearrange-
ment of the 99 loop; this rearrangement might form part
of the mechanism by which the cofactor fVIIIa increases
the reactivity of fIXa for fX 106–107-fold. 
Low molecular weight inhibitors of trypsin-like enzymes
(e.g., anticoagulants directed against thrombin and fXa),
usually bind into the S1–S4 sites, employing the gener-
ally hydrophobic nature of these binding pockets. The
observation that either S2 or S3/S4 are blocked by
Tyr99 may be one reason that no potent low molecular
weight active-site inhibitor for fIXa has been reported so
far. Our results suggest that a canonical binding mode of
these inhibitors is energetically unfavorable. Potent and
specific inhibitors of fIXa must either extend into the
primed binding sites of the enzyme, to increase the
binding surface, or take into account the atypical confor-
mation of Tyr99 in the active site, deviating significantly
from peptide substrate character.
Materials and methods
Recombinant desGla–desEGF1 fIX (residues 85–415) was synthe-
sized in Escherichia coli, purified, and activated as described previ-
ously [21]. PABA was purchased from Sigma (Deisenhofen, Germany).
All other reagents were purchased from various manufactures in the
highest grade available.
rfIXa was inhibited with 2 mM PABA and crystallized in 100 mM Tris
(pH 8.0), 25% t-butanol, 10 mM CaCl2 at a concentration of 10 mg/ml at
4°C using the sitting-drop vapor diffusion technique. Crystals with
dimensions 0.1 × 0.1 × 0.3 mm3 grew after four months and belonged to
hexagonal space group P6122 with unit-cell constants a =b = 90.9 Å,
c = 151.6 Å, α = β = 90°, γ = 120°. Data to 2.8 Å resolution were col-
lected on a Siemens (now Bruker AXS) multiwire area detector and
processed with SAINT data reduction software and programs from the
CCP4 suite [39]. The structure was solved by molecular replacement
Research Article  Crystal structure of human factor IXa Hopfner et al.    995
using coordinates from PPACK inhibited porcine fIXa as the search mol-
ecule [18] (PDB entry 1PFX). Rotational and translational searches were
performed with AMORE [40] using data from 15.0 to 3.5 Å. A single
solution was found with a correlation factor of 56.5% and an R factor of
39.7%. Crystallographic refinement and model building was performed
with the programs X-PLOR [41] and MAIN [42] using a total of 9397
reflections in the range 25.0 to 2.8 Å. The data used for refinement were
92.7% complete to 2.8 Å (82% completeness in the 2.80–2.93 Å shell)
with an Rmerge of 7.7% (last shell 31.6%). Refinement to an Rcryst of
21.6% (Rfree 27.3%) included rigid-body minimization, overall tempera-
ture refinement, bulk-solvent correction, positional refinement, restrained
individual temperature-factor refinement (root mean square B factors for
bonds and angles were 1.8 Å2 and 3.1 Å2, respectively) and manual
model building against 2Fo–Fc and Fo–Fc electron-density maps. The
final model contained 16 water molecules, a calcium ion and a t-butanol
molecule. The root mean square deviation of bond lengths from ideal
geometry was 0.007 Å and that of bond angles was 2.0°.
Accession numbers
The coordinates of fIXa in complex with p-aminobenzamidine have
been deposited in the Protein Data Bank with accession code 1RFN.
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